Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.34M.
Overvalued
The company’s latest PE is -0.73, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.35M shares, decreasing 3.15% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.